

Struggling to find Tivicay at your pharmacy? Learn why Dolutegravir can be hard to find in 2026, from discontinued strengths to specialty distribution.
You go to pick up your prescription, and the pharmacy tells you they don't have Tivicay in stock. Or worse — they can't get it for days. If this sounds familiar, you're not imagining things. Tivicay (Dolutegravir) has become harder for many patients to find, and there are real reasons behind it.
In this post, we'll break down exactly why Tivicay can be difficult to find in 2026 and what you can do about it.
Tivicay is the brand name for Dolutegravir, an integrase strand transfer inhibitor (INSTI) used to treat HIV-1 infection. It's made by ViiV Healthcare, a subsidiary of GSK. Tivicay works by blocking the enzyme that HIV needs to insert its genetic material into your cells, stopping the virus from multiplying.
Tivicay is taken once daily (50 mg) as part of a combination antiretroviral therapy regimen. It's one of the most widely recommended HIV medications, known for its strong effectiveness and generally manageable side effects.
There are several reasons you might be running into availability issues with Tivicay in 2026:
In January 2024, ViiV Healthcare discontinued the 10 mg and 25 mg tablets of Tivicay. Only the 50 mg film-coated tablets remain available for adults. If your previous dose relied on those lower-strength tablets, your pharmacy may have had trouble sourcing them — or needed to work with your prescriber to adjust your regimen.
Tivicay is still under patent protection in the United States. The earliest a generic version of Dolutegravir could become available is June 2030. Without generic competition, there's only one manufacturer producing the drug, which limits supply flexibility.
Many HIV medications, including Tivicay, are classified as specialty drugs. This means they may not be stocked at every retail pharmacy. Some insurance plans require you to fill Tivicay through a specific specialty pharmacy or mail-order service, which can add delays and limit your options.
Some insurance plans have shifted their preferred HIV regimens toward combination products like Dovato or Biktarvy. If your plan no longer lists standalone Tivicay as a preferred drug, your pharmacy may carry less of it — or your insurer may push you toward a different medication entirely.
If you're struggling to find Tivicay in stock, here are some practical steps:
Tivicay is an effective and widely trusted HIV medication — but that doesn't mean it's always easy to find. Between discontinued strengths, patent exclusivity, and specialty distribution requirements, patients can face real hurdles. The good news is that tools like Medfinder and open communication with your healthcare team can help you stay on track with your treatment.
For more tips on finding your medication, check out our guide on how to find Tivicay in stock near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.